Public Statement 10/21/21
On behalf of the Board of Trustees, I’m pleased to announce the appointment of Robert S. Copeland (He/Him) as the Interim CEO of Equitas Health.
Robert has been part of the Equitas Health family for many years, initially serving as a member of the Board of Trustees prior to joining the staff four years ago as Chief Development Officer. In addition to his current experience on the leadership team, Robert brings more than 30 years of experience in healthcare and non-profit fundraising to the role. His record speaks for itself: Thanks to Robert’s relentless efforts and strong relationships with donors and partners, Equitas Health’s major gifts program has expanded, along with donor engagement. The Development team has secured more than $9.5 million since Robert became Chief Development Officer, including a fundraising record of $1 million from the Art for Life charity art auction.
The Board is confident Robert’s unique perspectives and trusted relationships will help Equitas Health navigate the current challenges. His passion is inspiring, and he is unwavering in his commitment to the mission. The Board is grateful Robert has agreed to take on these additional responsibilities as we conduct a robust national search for our future CEO.
If you have any questions, please do not hesitate to reach out directly to Robert. On behalf of the Board of Trustees, I hope you will join us in thanking him for taking on this critical role.
Respectfully,
Sam Rinehart, Board Chair, Equitas Health
Public Statement 3/28/25
Public Statement 12/10/24
Public Statement 9/21/24
Our focus remains on integrating our programs to better serve historically neglected communities, always with an understanding of the unique and intersectional needs of the diverse LGBTQ+ population.
Public Statement 8/26/24
Johnson & Johnson, one of the world’s largest drugmakers, announced last Friday that it will discontinue upfront 340B pricing on two medications for disproportionate share hospital (DSH) covered entities. The move is part of a sustained campaign by large drug manufacturers to undermine the federal 340B Drug Pricing Program for participating hospitals and covered entities such as Equitas Health.
Public Statement 3/28/25
